Abstracts tagged "cyclophosphamide"

Abstract Number: 047 • 2023 Pediatric Rheumatology Symposium
Clinical Characteristics and Outcomes of North American Youth with Lupus Nephritis Requiring Dialysis Treated with Cyclophosphamide
Christine Wang¹, Rebecca Sadun², Wenru Zhou³, Kristen Miller³, Claire Palmer³, Stacy Ardoin⁴, Christine Bacha⁵, Emily Hause⁶, Joyce Hui-Yuen⁷, Nicole Ling⁸, Maria Pereira⁹, Meredith Riebschleger¹, Kelly Rouster-Stevens¹⁰, Aliese Sarkissian¹¹, Julia Shalen¹², William Soulsby¹³, Marinka Twilt¹⁴, Eveline Wu¹⁵, Laura Lewandowski¹⁶, Scott Wenderfer¹⁷ and Jennifer Cooper¹⁸, ¹University of Michigan, Ann Arbor, MI, ²Duke University, Durham, NC, ³University of Colorado, Denver, CO, ⁴Nationwide Children's Hospital, Columbus, OH, ⁵Akron Children's Hospital, Akron, OH, ⁶University of Minnesota, Minneapolis, MN, ⁷Cohen Children's Medical Center, Northwell Health, Lake Success, New York; Center for Autoimmune, Musculoskeletal, and Hematopoietic Diseases Research, Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, ⁸UCSF, San Francisco, CA, ⁹Baylor College of Medicine, Houston, TX, ¹⁰Emory University/Children's Healthcare of Atlanta, Atlanta, GA, ¹¹UNC- Chapel Hill, Durham, NC, ¹²Johns Hopkins University, Baltimore, MD, ¹³University of California, San Francisco, San Francisco, CA, ¹⁴Alberta Children's Hospital, Calgary, AB, Canada, ¹⁵UNC Chapel Hill, Chapel Hill, NC, ¹⁶NIAMS, NIH, Bethesda, MD, ¹⁷British Columbia Children's Hospital, Vancouver, BC, Canada, ¹⁸University of Colorado/Children's Hospital Colorado, Denver, CO
Background/Purpose: Few studies have evaluated the clinical characteristics and outcomes of youth with lupus nephritis (LN) treated with cyclophosphamide (CYC) who initially required kidney replacement…
Abstract Number: 0433 • ACR Convergence 2021
Use of 2-Mercaptoethane Sodium Sulfonate Prophylaxis in Cyclophosphamide-Treated Patients with ANCA-Associated Vasculitis: Results of an Electronic Survey
Lukas Joos¹, Solange Gonzalez Chiappe¹, Thomas Neumann¹ and Alfred Mahr², ¹Kantonsspital St.Gallen, St.Gallen, Switzerland, ²Kantonsspital St. Gallen, St.Gallen, Switzerland
Background/Purpose: Co-prescribing mesna with CYC for AAV aims to prevent the potential urotoxic effects of CYC. We investigated current clinical practice related to prescribing mesna…
Abstract Number: 1460 • ACR Convergence 2021
Lupus Nephritis Renal Responses in Relation to Treatment and Demographics: Observations from a Multi-racial/ethnic Cohort of 159 Patients in the NYU Lupus Registry
Mayce Haj-Ali¹, Kristina Deonaraine², Alexis Engel³, Yingzhi Qian¹, Amit Saxena⁴, Peter Izmirly², Jill Buyon⁴ and H. Michael Belmont⁴, ¹NYU Grossman School of Medicine, New York, NY, ²New York University School of Medicine, New York, NY, ³NYU Langone Health, New Yok, NY, ⁴NYU School of Medicine, New York, NY
Background/Purpose: Lupus nephritis (LN) disproportionately affects racial and ethnic populations. Contreras reported African-American (AA) and Hispanic patients had worse outcomes as compared to patients of…
Abstract Number: 126 • 2020 Pediatric Rheumatology Symposium
Cyclophosphamide as Rescue Therapy for Kawasaki Disease with Peripheral Vascular Disease: A Single Center Experience
Ugo Awa¹, Monica Bray ² and Marietta De Guzman ³, ¹Baylor College of Medicine, Houston, ²Section of Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, ³Section of Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas
Background/Purpose: Kawasaki Disease (KD) is the most common systemic vasculitis affecting children 5 years and younger. With coronary vessel involvement, KD is now the most…
Abstract Number: 141 • 2020 Pediatric Rheumatology Symposium
Cyclophosphamide Use in Treatment of Refractory Kawasaki Disease: A Single Center Case Series of 10 Patients and Literature Review
Olha Halyabar¹, Mary Beth Son ², Margaret Chang ³ and Robert Sundel ¹, ¹Children's Hospital/Boston Medical Center, Boston, ²Boston Children's Hospital, Boston, Massachusetts, ³Boston Children's Hospital, Boston
Background/Purpose: Intravenous immunoglobulin (IVIG) effectively treats vasculitis of the coronary arteries in the large majority of Kawasaki Disease (KD) patients. However, approximately 25% of patients…
Abstract Number: 2632 • 2019 ACR/ARP Annual Meeting
Changing Trends in the Management of ANCA-associated Vasculitis at an Academic Medical Center
Sana Afroz¹ and Najia Shakoor ², ¹RUMC, Chicago, IL, ²Rush University Medical Center, Chicago, IL
Background/Purpose: For years, cyclophosphamide (CYC) has been the primary treatment for severe anca-associated vasculitides (AAV) and has significantly improved disease related mortality. In addition, maintenance…
Abstract Number: 2633 • 2019 ACR/ARP Annual Meeting
Efficacy of Remission Induction Regimens in Elderly Patients with ANCA-Associated Glomerulonephritis
Audrey Hopkins¹, Stanley Chu ², Philip Seo ³, Eric Gapud ¹, Brendan Antiochos ¹, Shaker Eid ¹, Jason Liebowitz ¹ and Duvuru Geetha ¹, ¹Johns Hopkins Bayview Medical Center, Baltimore, ²Johns Hopkins University, Baltimore, ³Johns Hopkins Medicine, Baltimore, MD
Background/Purpose: Induction regimens using either cyclophosphamide (CYC) or rituximab (RTX) have been shown to have similar efficacy and similar rates of adverse events in randomized…
Abstract Number: 812 • 2018 ACR/ARHP Annual Meeting
Inflammatory Stays Inflammatory: A Subgroup of Systemic Sclerosis Characterized By High Morbidity and Inflammatory Resistance to Cyclophosphamide
Aleksey Mitev¹, Daria Feldmann¹, Moritz Binder², Kim Möller³, Anna-Maria Kanne¹, Thomas Hügle⁴, Peter M. Villiger⁵, Reinhard Voll⁶, Stephanie Finzel¹ and Florian Kollert⁷, ¹Department of Rheumatology and Clinical Immunology, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany, ²Department of Internal Medicine, Mayo Clinic, Rochester, MN, ³Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ⁴Rheumatology, University Hospital Lausanne (CHUV), Lausanne, Switzerland, ⁵Rheumatology and Clin Immunol, Bern, Switzerland, ⁶Clinic for Rheumatology and Clinical Immunology, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany, ⁷Department of Rheumatology, Immunology, and Allergology, Inselspital, University Hospital Bern, Bern, Switzerland
Background/Purpose: Elevated levels of C-reactive protein (CRP) in systemic sclerosis (SSc) have been linked to early inflammatory stages of the disease. This study has been…
Abstract Number: 1728 • 2018 ACR/ARHP Annual Meeting
Pharmacokinetics of Cyclophosphamide in Scleroderma Treated By Cyclophosphamide Versus Transplantation
David Adams¹, Keith Sullivan², Ivan Spasojevic¹, Ping Fan¹, Mario Sampson³, Michael Cohen-Wolkowiez³, E. William St Clair⁴, Rob Woolson⁵, Jan Storek⁶, Mary Ellen Csuka⁷, Ashley Pinckney⁵, Beverly Welch⁸, Ellen Goldmuntz⁹, Daniel E. Furst¹⁰, Leslie Crofford¹¹, Lynette Keyes-Elstein¹², Maureen Mayes¹³, Peter McSweeney¹⁴ and Richard Nash¹⁴, ¹Medicine, Duke University Medical Center, Durham, NC, ²Duke University Medical Center, Durham, NC, ³Pediatrics-Infectious Disease, Duke University Medical Center, Durham, NC, ⁴Rheumatology, Duke University Medical Center, Durham, NC, ⁵Rho Federal Systems, Inc., Chapel Hill, NC, ⁶University of Calgary, Calgary, AB, Canada, ⁷Medicine, Medical College of Wisconsin, Milwaukee, WI, ⁸National Institutes of Health, Bethesda, MD, ⁹NIAID, NIH, Bethesda, MD, ¹⁰University of Washington, Seattle, WA, ¹¹Division of Rheumatology and Immunology, Vanderbilt University Medical Center, Nashville, TN, ¹²Clinical Statistics, Rho Federal Systems, Inc., Chapel Hill, NC, ¹³Rheumatology, University of Texas at Houston, Houston, TX, ¹⁴Colorado Blood Cancer Institute, Denver, CO
Background/Purpose: The pharmacokinetics (PK) of cyclophosphamide (CP) and its primary active metabolite, 4-hydroxycyclophosphamide (4-OH-CP) have not been adequately studied in scleroderma. The hypothesis of this…
Abstract Number: 1820 • 2018 ACR/ARHP Annual Meeting
Myeloablative Autologous Hematopoietic Stem Cell Transplantation for Severe Scleroderma: Long-Term Outcomes 6-11 Years after Entry on a Randomized Study Comparing Transplantation and Cyclophosphamide
Keith Sullivan¹, Ashley Pinckney², Ellen Goldmuntz³, Beverly Welch⁴, Dinesh Khanna⁵, Robert W. Simms⁶, Suzanne Kafaja⁷, George Georges⁸, Jan Storek⁹, Mary Ellen Csuka¹⁰, Richard Nash¹¹, Daniel E. Furst¹², Leslie Crofford¹³, Peter McSweeney¹¹, Maureen D. Mayes¹⁴ and Lynette Keyes-Elstein¹⁵, ¹Duke University Medical Center, Durham, NC, ²Rho Federal Systems, Inc., Chapel Hill, NC, ³NIAID, NIH, Bethesda, MD, ⁴National Institutes of Health, Bethesda, MD, ⁵Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, ⁶Rheumatology, Boston University School of Medicine, Boston, MA, ⁷David Geffen School of Medicine, UCLA, Los Angeles, CA, ⁸Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, ⁹University of Calgary, Calgary, AB, Canada, ¹⁰Medicine, Medical College of Wisconsin, Milwaukee, WI, ¹¹Colorado Blood Cancer Institute, Denver, CO, ¹²University of Washington, Seattle, WA, ¹³Division of Rheumatology and Immunology, Vanderbilt University Medical Center, Nashville, TN, ¹⁴Rheumatology, University of Texas McGovern Medical School, Houston, TX, ¹⁵Clinical Statistics, Rho Federal Systems, Inc., Chapel Hill, NC
Background/Purpose: The Scleroderma: Cyclophosphamide or Transplantation (SCOT) trial demonstrated that for adults with severe scleroderma (ACR 1995 criteria) and internal organ involvement, myeloablative CD34+selected autologous…
Abstract Number: 2647 • 2018 ACR/ARHP Annual Meeting
Comparison of Low-Dose Intravenous Cyclophosphamide with Oral Mycophenolate Mofetil in the Treatment of Lupus Nephritis: Long Term Follow-up Data
Manish Rathi¹, Aman Sharma², Joyita Sharma³ and Krishan L Gupta³, ¹Department of Nephrology,, Postgraduate Institute of Medical Education and Research, Chandigarh, India, ²Clinical Immunology and Rheumatology Services, Department of Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India, Chandigarh, India, ³Nephrology, Post Graduate Institute of Medical Education and Research, Chandigarrh, India
Background/Purpose: We present the long-term follow-up of patients with lupus nephritis who completed the randomized controlled trial on comparison of low-dose intravenous cyclophosphamide (IV CYC)…
Abstract Number: 2693 • 2018 ACR/ARHP Annual Meeting
What Is the Effect of Cyclophosphamide Iv Pulse Therapy in Patients with Diffuse Cutaneous Systemic Sclerosis on Skin Involvement: An Observational Study
Brigit Kersten, Nathan den Broeder, Frank van den Hoogen, Els van den Ende and Madelon Vonk, Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands
Background/Purpose: Patients with systemic sclerosis who have proximal skin involvement are classified as diffuse cutaneous systemic sclerosis (DcSSc). Patients with progressive skin involvement have worse prognosis.…
Abstract Number: 2742 • 2018 ACR/ARHP Annual Meeting
Rituximab Versus Cyclophosphamide for Vasculitic Neuropathy: A Patient Reported Outcomes Study
Aditi Patel¹, Kevin Byram², Yuxuan Jin³, Alexander Wu¹, Yuebing Li⁴, Leonard H. Calabrese⁵ and Rula A Hajj-Ali⁶, ¹Internal Medicine, Cleveland Clinic, Cleveland, OH, ²Cleveland Clinic Foundation, Cleveland, OH, ³Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, ⁴Department of Neurology, Cleveland Clinic, Cleveland, OH, ⁵Rheumatic & Immunologic Dis, Cleveland Clinic, Cleveland, OH, ⁶Rheumatic and Immunologic Disease, Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose: Vasculitic neuropathy (VN) is a major complication of systemic vasculitis and contributes to morbidity, functional limitation, and health care utilization in affected patients. Patient…
Abstract Number: 31 • 2017 ACR/ARHP Annual Meeting
Single Cell Analysis Revealed That the Response to Cyclophosphamide Therapy Is Regulated By B Cells in Systemic Sclerosis-Associated Interstitial Lung Disease
Satoshi Ebata¹, Ayumi Yoshizaki², Takemichi Fukasawa¹, Kouki Nakamura¹, Maiko Hirakawa¹, Takashi Yamashita¹, Shunsuke Miura³, Ryosuke Saigusa¹, Megumi Hirabayashi¹, Asako Yoshizaki¹, Kaname Akamata¹, Yoshihide Asano⁴, Yutaka Kazoe⁵, Kazuma Mawatari⁵, Takehiko Kitamori⁵ and Shinichi Sato⁶, ¹Dermatology, University of Tokyo, Graduate School of Medicine, Tokyo, Japan, ²Department of Dermatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ³University of Tokyo, Graduate School of Medicine, Tokyo, Japan, ⁴Applied Chemistry, University of Tokyo, Graduate School of Medicine, Tokyo, Japan, ⁵Applied Chemistry, University of Tokyo, Graduate School of Engineering, Tokyo, Japan, ⁶Department of Dermatology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Japan
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease characterized by fibrosis of several organs. SSc-associated interstitial lung disease (ILD) is a frequent and severe complication…
Abstract Number: 749 • 2017 ACR/ARHP Annual Meeting
Treatment with Cyclophosphamide for Systemic Sclerosis-Interstitial Lung Disease Does Not Lead to a Sustained Improvement in Lung Function in Two Independent Cohorts
Elizabeth R. Volkmann¹, Donald P. Tashkin¹, Myung Sim¹, Ning Li², Dinesh Khanna³, Michael Roth⁴, Philip J. Clements⁴, Anna-Maria Hoffmann-Vold⁵, Daniel E. Furst¹, Grace Kim⁶, Jonathan Goldin¹ and Robert Elashoff⁷, ¹University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ²Biomathematics, University of California, Los Angeles, Los Angeles, CA, ³University of Michigan, Ann Arbor, MI, ⁴Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁵Oslo University Hospital, Oslo, Norway, ⁶Radiology, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁷University of California, Los Angeles, Los Angeles, CA
Background/Purpose: Compared with placebo, treatment with cyclophosphamide (CYC) improved lung function in patients with systemic sclerosis-related interstitial lung disease (SSc-ILD) after 1 year in Scleroderma…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].